aibioKOD Kodiak Sciences Inc
Kodiak Sciences (KOD) news
Top story · Aug 13, 2026 · Company press release
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
Latest Kodiak Sciences news
We have not published a story on Kodiak Sciences yet. When there is news, it will appear here.
What Kodiak Sciences does
Kodiak Sciences develops next-generation therapeutics for retinal diseases using its Antibody Biopolymer Conjugate, or ABC, platform, with the goal of preventing and treating the major causes of blindness. Its lead investigational medicine, tarcocimab tedromer, also called Zenkuda or KSI-301, is an anti-VEGF therapy with a mean ocular half-life in humans of 20 days. The company says Zenkuda has completed four Phase 3 pivotal studies, in diabetic retinopathy, retinal vein occlusion and wet AMD. The Phase 3 DAYBREAK study in wet AMD has completed enrollment and is testing both Zenkuda and KSI-501, an anti-IL-6 VEGF-trap bispecific therapy, with topline results expected in 3Q 2026. KSI-101, a high strength bispecific protein targeting IL-6 and VEGF, is being developed for macular edema secondary to inflammation in the Phase 3 PEAK and PINNACLE studies, with topline readouts expected in 4Q 2026 and 2Q 2027. Kodiak is also extending its platform to conjugate small molecules to its biopolymer backbone. It has commissioned Ursus, a commercial-scale drug substance facility built with Lonza, and the company says it retains all global rights to its product candidates.
| Product or program | What it is | Stage |
|---|---|---|
| Zenkuda (tarcocimab tedromer, KSI-301) | Anti-VEGF intravitreal therapy built on the ABC platform for retinal vascular disease | Phase 3; four pivotal studies completed |
| KSI-501 | Anti-IL-6 VEGF-trap bispecific therapy for wet AMD | Phase 3 (DAYBREAK) |
| KSI-101 | High strength bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation | Phase 3 (PEAK and PINNACLE) |
Kodiak Sciences annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $182.4 million | $126.1 million |
| Net income (loss) | -$230.0 million | -$176.2 million |
| Cash from operations | -$136.0 million | -$117.3 million |
| Cash and equivalents | $209.9 million | $168.1 million |
Questions about Kodiak Sciences
What is the ticker symbol of Kodiak Sciences?
Kodiak Sciences Inc trades under the ticker KOD on NASDAQ.
Where is Kodiak Sciences listed?
Kodiak Sciences Inc is listed on NASDAQ. Our directory also records these other listings: BIVA:KOD; BMV:KOD; GETTEX:K27; LS:A2N6P0; LSX:A2N6P0.
What is the SEC CIK of Kodiak Sciences?
The SEC Central Index Key (CIK) for Kodiak Sciences Inc is 1468748. Its filings are on SEC EDGAR.
How many shares does Kodiak Sciences have outstanding?
62,849,457 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Kodiak Sciences listed under?
Our directory records Kodiak Sciences Inc under United States.
What does Kodiak Sciences do?
Our directory classifies Kodiak Sciences Inc as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Kodiak Sciences?
The ISIN recorded for Kodiak Sciences Inc is US50015M1099.
Does aibio.space cover Kodiak Sciences?
aibio.space lists Kodiak Sciences Inc among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Kodiak Sciences incorporated?
SEC records list its state or country of incorporation as DE.
What does Kodiak Sciences develop?
Kodiak Sciences develops next-generation therapeutics for retinal diseases using its Antibody Biopolymer Conjugate, or ABC, platform, with the goal of preventing and treating the major causes of blindness. Its lead investigational medicine, tarcocimab tedromer, also called Zenkuda or KSI-301, is an anti-VEGF therapy with a mean ocular half-life in humans of 20 days.
What is Zenkuda (tarcocimab tedromer, KSI-301) from Kodiak Sciences?
Zenkuda (tarcocimab tedromer, KSI-301): Anti-VEGF intravitreal therapy built on the ABC platform for retinal vascular disease Stage: Phase 3; four pivotal studies completed.
What is KSI-501 from Kodiak Sciences?
KSI-501: Anti-IL-6 VEGF-trap bispecific therapy for wet AMD Stage: Phase 3 (DAYBREAK).
Is Kodiak Sciences profitable?
Kodiak Sciences Inc reported a net loss of $230.0 million for the fiscal year ended Dec 31, 2025, and used $136.0 million of cash in operations, per its annual report to the SEC.
How much does Kodiak Sciences spend on research and development?
$182.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Kodiak Sciences have?
$125.9 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Kodiak Sciences
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Kodiak Sciences Inc.
- CIK
- 1468748
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- KOD (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1250 PAGE MILL RD, PALO ALTO, CA, 94304
- Phone
- 650-281-0850
- Shares outstanding
- 62,849,457 as of 2026-08-06 (10-Q filed 2026-08-13)
- Former names
- Oligasis, LLC
Recent filings
Listing details
- Company
- Kodiak Sciences Inc
- Ticker
- KOD
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US50015M1099
- Other listed symbols
- BIVA:KOD; BMV:KOD; GETTEX:K27; LS:A2N6P0; LSX:A2N6P0
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction